Is zosano Pharma (ZSAN) a buy or sell?
According to the issued ratings of 2 analysts in the last year, the consensus rating for Zosano Pharma stock is Buy based on the current 2 buy ratings for ZSAN. The average twelve-month price target for Zosano Pharma is $2.25 with a high price target of $2.50 and a low price target of $2.00. Learn more
Where can I buy shares of ZSAN?
Shares of ZSAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is the upside for zosano Pharma (Zoso) stock?
According to analysts, Zosano Pharma's stock has a predicted upside of 113.72% based on their 12-month price targets. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
What is zosano Pharma's net margin and return on equity?
Zosano Pharma had a negative net margin of 3,367.90% and a negative trailing twelve-month return on equity of 75.96%. View Zosano Pharma's earnings history.
Is ZSAN a good stock to buy?
The consensus among Wall Street equities research analysts is that investors should "hold" Zosano Pharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZSAN, but not buy additional shares or sell existing shares.
What does zosano Pharma do?
Zosano Pharma is a clinical-stage biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary transdermal microneedle patch system.
What happened to Zosano Pharma?
Shares of Zosano Pharma Corp. lost nearly half of their value and hit a new all-time low on Thursday after the cash-strapped biopharmaceutical company filed for chapter 11 bankruptcy with plans to close up shop.
Will zosano Pharma go up?
The 1 analysts offering 12-month price forecasts for Zosano Pharma Corp have a median target of 21.00, with a high estimate of 21.00 and a low estimate of 21.00. The median estimate represents a +7,677.78% increase from the last price of 0.27.
Will Qtrypta be approved?
Zosano filed for approval of Qtrypta in December 2019 and disclosed news of the FDA's acceptance of the submission for review the following March, resulting in a PDUFA date in October 2020. A late 2021 resubmission could see Qtrypta win FDA approval up to two years later than originally planned.
Is zosano Pharma going out of business?
Zosano Pharma has run out of road. After working to find a strategic alternative in the wake of the FDA's refusal to review its submission, the transdermal drug delivery specialist has now filed for paperwork for Chapter 11 bankruptcy.
What is Qtrypta?
Qtrypta is Zosano's proprietary investigational formulation of zolmitriptan delivered utilizing its proprietary transdermal microneedle system (the “System”) in development for the acute treatment of migraine.
Should I buy or sell Zosano Pharma stock right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zosano Pharma in the last year. There are currently 2 hold ratings and 1 b...
What is Zosano Pharma's stock price forecast for 2022?
3 analysts have issued 12-month price targets for Zosano Pharma's shares. Their forecasts range from $70.00 to $70.00. On average, they expect Zosa...
How has Zosano Pharma's stock performed in 2022?
Zosano Pharma's stock was trading at $16.45 at the start of the year. Since then, ZSAN shares have decreased by 96.6% and is now trading at $0.5576...
Are investors shorting Zosano Pharma?
Zosano Pharma saw a drop in short interest during the month of May. As of May 31st, there was short interest totaling 332,300 shares, a drop of 15....
When is Zosano Pharma's next earnings date?
Zosano Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Zosano...
How were Zosano Pharma's earnings last quarter?
Zosano Pharma Co. (NASDAQ:ZSAN) announced its quarterly earnings data on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per...
When did Zosano Pharma's stock split? How did Zosano Pharma's stock split work?
Shares of Zosano Pharma reverse split on the morning of Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022....
Who are Zosano Pharma's key executives?
Zosano Pharma's management team includes the following people: Mr. Steven Lo , Sr. VP of Operations, Pres, CEO & Director (Age 55, Pay $534.08k)...
Who are some of Zosano Pharma's key competitors?
Some companies that are related to Zosano Pharma include Bellicum Pharmaceuticals (BLCM) , Sonoma Pharmaceuticals (SNOA) , Medicure (MCUJF) , X...
What is the ZSAN symbol?
What is Zosano Pharma?
Zosano Pharma trades on the NASDAQ under the ticker symbol "ZSAN."
What is the P/E ratio of Zosano Pharma?
Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system. The company was founded in October 2006 and is headquartered in Fremont, CA.
When did Zosano Pharma reverse split?
The P/E ratio of Zosano Pharma is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is Zosano Pharma a buy?
Zosano Pharma shares reverse split on the morning of Friday, January 26th 2018. The 1-20 reverse split was announced on Thursday, January 25th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2018.
Does Zosano Pharma have research coverage?
Zosano Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Does Zosano Pharma pay dividends?
Zosano Pharma has received no research coverage in the past 90 days.
When did Zosano Pharma buy signal 2021?
Zosano Pharma does not currently pay a dividend.
Does Zosano Pharma stock have sell signals?
A buy signal was issued from a pivot bottom point on Monday, July 19, 2021, and so far it has risen 0.12%. Further rise is indicated until a new top pivot has been found. Zosano Pharma Corp has increased volume and follows the last lift in the price.
Is Zosano Pharma Corp stock A Buy?
The Zosano Pharma Corp stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock.
Which stocks are similar to ZSAN?
Zosano Pharma Corp holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
What is the quality of ZSAN?
Stocks that are quantitatively similar to ZSAN, based on their financial statements, market capitalization, and price volatility, are INFI, GNCA, ATNM, ARAV, and AYLA.
What is Zosano Pharma Corporation?
ZSAN has a Quality Grade of F, ranking ahead of 0.35% of graded US stocks.
What is Zosano patch?
Zosano Pharma Corporation provides biopharmaceutical products and services. The Company specializes in biopharmaceuticals, peptides, small water soluble molecules, monoclonal antibodies, and vaccines for the treatment of severe osteoporosis.
How does MarketBeat calculate stock ratings?
Zosano’s patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator. “We are pleased t
Does Zosano Pharma outperform?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
What is Zosano Pharma Corporation?
MarketBeat users like Zosano Pharma stock more than the stock of other Medical companies. 73.19% of MarketBeat users gave Zosano Pharma an outperform vote while medical companies recieve an average of 67.31% outperform votes by MarketBeat users.
How many sectors are there in Zacks?
Zosano Pharma Corporation is a biopharmaceutical company. It is engaged in developing a transdermal micro needle patch system to deliver formulations of existing drugs through the skin for the treatment of a variety of indications.
What are the different grades for stocks?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
Is ZacksTrade a separate company?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
